现实世界的系统性治疗模式,生存结果和晚期肝细胞癌的预后因素:来自低资源环境的15年经验
Jirapat Wonglhow1, Chirawadee Sathitruangsak1, Patrapim Sunpaweravong1
1Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Cancers
|September 13, 2025
概括
在晚期肝细胞癌 (HCC) 中,由于免疫疗法 (IO) 的成本限制,氨酸激酶抑制剂 (TKI) 是关键. 顺序治疗显著提高了生存率,化疗在资源有限的环境中是可行的选择.
科学领域:
- 在瘤学瘤学.
- 肝病学 肝病学是一种肝病学.
- 药物经济学 药物经济学
背景情况:
- 先进的肝细胞癌 (HCC) 治疗正在发展,但新药的获取受到高成本的限制.
- 在资源有限的环境中,对系统性治疗模式和结果的真实数据至关重要.
研究的目的:
- 评估高级HCC的全身治疗模式和生存结果.
- 在现实世界资源限制下分析治疗序列.
主要方法:
- 对接受全身治疗的330名晚期HCC患者 (2010-2024) 的回顾性研究.
- 对总生存 (OS),无进展生存 (PFS) 和客观反应率 (ORR) 的分析.
- 对OS的预后因素的调查.
主要成果:
- 第一线治疗主要涉及铁激酶抑制剂 (TKIs; 69.7%).
- 在一线治疗中,中位数的生存期在7.2至10.9个月之间,PFS在2.69至6.19个月之间.
- 多线疗法 (4.5至40.7个月) 显著改善了整体存活率.
结论:
- 在资源有限的环境中,TKIs是高级HCC的主要有效治疗方法.
- 序列性全身疗法改善了生存率,突出了治疗适宜性保护的必要性.
- 在资源有限的环境中,化疗仍然是高级HCC的可行选择.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
08:25Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
740
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
